January 19, 2018 / 6:05 AM / a year ago

BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

Jan 19 (Reuters) - BAVARIAN NORDIC A/S:

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

* OPEN-LABEL PHASE 1 TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF MVA-BN(®) BRACHYURY VACCINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below